Ficerafusp alfa enters phase 2/3 trial for recurrent/metastatic head and neck cancer, evaluating its combination with Keytruda for first-line treatment.
The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback